Companies

Boerner warned a year ago that BMS may see its revenue falter in the middle of this decade and the company’s 2025 guidance suggests that will happen this year after 2024 beat consensus.

In September last year, J&J lost a court case surrounding its 2019 purchase of Auris health, and was ordered to pay over $1bn in damages. Reactions to the potentially precedent-setting news were harsh and quick. In Vivo spoke to legal, M&A and BD experts from across the medtech industry to learn more about the true impacts.

Takeda’s head of gastroenterology talked to In Vivo about the major’s plans for finding biomarkers for Crohn’s disease as part of a Euro-wide prevention and interception trial.

Now that one of the most controversial pharma M&As of 2024 has closed, did overtures to concerned customers and extended prenotification discussions help Novo and Catalent seal the deal?

Repatha was not an overnight success, but the work Amgen has done to turn its PCSK9 inhibitor into a blockbuster is informing its strategy for Lp(a)-reducing olpasiran and obesity drug MariTide.

CEO Daniel O’Day and EVP-research Flavius Martin highlighted Gilead’s inflammation R&D and dealmaking focus at the recent J.P. Morgan meeting.

Boston-area biotech Apnimed expects Phase III readouts for its obstructive sleep apnea combination drug by May. Patients with OSA are desperate for a pill to treat the condition, and GLP-1 agonists are only part of the solution.

Having spun out its oncology business and put all of its eggs into a neuroscience-shaped basket, how is Alkermes executing on its 2024 stated strategy to return to its CNS roots?

Juho Jalkanen, CEO of Faron Pharma, discusses the importance of addressing unmet medical needs in cancer through breaking treatment resistance and developing long-term solutions, as well as the potential of its Phase II asset bexmarilimab.

Manu Chakravarthy, Roche’s head of the resurrected cardiometabolic division, lays out his four-pillared strategy to place the company in direct competition with Eli Lilly and Novo Nordisk.